JP6385334B2 - 糖類の化粧的および医薬的使用 - Google Patents
糖類の化粧的および医薬的使用 Download PDFInfo
- Publication number
- JP6385334B2 JP6385334B2 JP2015500983A JP2015500983A JP6385334B2 JP 6385334 B2 JP6385334 B2 JP 6385334B2 JP 2015500983 A JP2015500983 A JP 2015500983A JP 2015500983 A JP2015500983 A JP 2015500983A JP 6385334 B2 JP6385334 B2 JP 6385334B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition
- ndo
- cosmetic
- melibiose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002537 cosmetic Substances 0.000 title claims description 60
- 235000000346 sugar Nutrition 0.000 title description 4
- 150000008163 sugars Chemical class 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 94
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 claims description 44
- 208000012641 Pigmentation disease Diseases 0.000 claims description 28
- 229920001542 oligosaccharide Polymers 0.000 claims description 27
- 150000002482 oligosaccharides Chemical class 0.000 claims description 26
- 230000000699 topical effect Effects 0.000 claims description 22
- 208000003351 Melanosis Diseases 0.000 claims description 19
- 230000002087 whitening effect Effects 0.000 claims description 19
- 208000000069 hyperpigmentation Diseases 0.000 claims description 18
- 230000003810 hyperpigmentation Effects 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 206010047642 Vitiligo Diseases 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000000516 sunscreening agent Substances 0.000 claims description 11
- 239000003981 vehicle Substances 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 208000007256 Nevus Diseases 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 230000001815 facial effect Effects 0.000 claims description 8
- 206010027145 Melanocytic naevus Diseases 0.000 claims description 6
- 206010014970 Ephelides Diseases 0.000 claims description 5
- 206010064127 Solar lentigo Diseases 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000000017 hydrogel Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000008833 sun damage Effects 0.000 claims description 3
- 206010040829 Skin discolouration Diseases 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 104
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 22
- 208000031019 skin pigmentation disease Diseases 0.000 description 22
- 238000004903 NDO Methods 0.000 description 20
- 238000011282 treatment Methods 0.000 description 17
- 150000001720 carbohydrates Chemical class 0.000 description 16
- 201000004624 Dermatitis Diseases 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 14
- 102000004890 Interleukin-8 Human genes 0.000 description 13
- 108090001007 Interleukin-8 Proteins 0.000 description 13
- 235000013325 dietary fiber Nutrition 0.000 description 12
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 12
- 229940096397 interleukin-8 Drugs 0.000 description 11
- 210000002510 keratinocyte Anatomy 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 229920001202 Inulin Polymers 0.000 description 9
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 9
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 description 8
- 230000000770 proinflammatory effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960000511 lactulose Drugs 0.000 description 7
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 7
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 6
- 229940107187 fructooligosaccharide Drugs 0.000 description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 6
- 229940029339 inulin Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- -1 sialic acid glycoside Chemical class 0.000 description 5
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229940127234 oral contraceptive Drugs 0.000 description 4
- 239000003539 oral contraceptive agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 3
- 206010040825 Skin depigmentation Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 150000004043 trisaccharides Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 2
- 241000234282 Allium Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- 244000003416 Asparagus officinalis Species 0.000 description 2
- 235000005340 Asparagus officinalis Nutrition 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- WMUHBTATSZQNJG-UHFFFAOYSA-N difructose anhydride iv Chemical compound C1OC(CO)(C(C2O)O)OC2COC2(CO)C(O)C(O)C1O2 WMUHBTATSZQNJG-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000021995 interleukin-8 production Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- HAAYBYDROVFKPU-UHFFFAOYSA-N silver;azane;nitrate Chemical compound N.N.[Ag+].[O-][N+]([O-])=O HAAYBYDROVFKPU-UHFFFAOYSA-N 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RFCVXVPWSPOMFJ-UHFFFAOYSA-N 2-[(2-azaniumyl-3-phenylpropanoyl)amino]-4-methylpentanoate Chemical compound CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960003055 bisoctrizole Drugs 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- KSRQDWNGXKYIDO-UHFFFAOYSA-N difructose anhydride III Natural products O1C2C(O)C(CO)OC2(CO)OCC21OC(CO)C(O)C2O KSRQDWNGXKYIDO-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003804 extraction from natural source Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000006099 transfructosylation Effects 0.000 description 1
- 229940051117 tri-luma Drugs 0.000 description 1
- ATTPXNCCXYEULE-JOBJWGHLSA-N triluma Chemical compound OC1=CC=C(O)C=C1.OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O ATTPXNCCXYEULE-JOBJWGHLSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1205177.7 | 2012-03-23 | ||
| GB1205177.7A GB2500585A (en) | 2012-03-23 | 2012-03-23 | Use of oligosaccharides to reduce skin pigmentation |
| PCT/GB2013/050705 WO2013140153A2 (en) | 2012-03-23 | 2013-03-19 | Cosmetic and pharmaceutical uses of saccharides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513357A JP2015513357A (ja) | 2015-05-11 |
| JP2015513357A5 JP2015513357A5 (enExample) | 2016-04-28 |
| JP6385334B2 true JP6385334B2 (ja) | 2018-09-05 |
Family
ID=46087042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500983A Active JP6385334B2 (ja) | 2012-03-23 | 2013-03-19 | 糖類の化粧的および医薬的使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10159635B2 (enExample) |
| EP (1) | EP2836190B1 (enExample) |
| JP (1) | JP6385334B2 (enExample) |
| KR (1) | KR102112728B1 (enExample) |
| ES (1) | ES2797535T3 (enExample) |
| GB (1) | GB2500585A (enExample) |
| WO (1) | WO2013140153A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102020133860A1 (de) | 2020-12-16 | 2022-06-23 | MNT Systeme GmbH | VERWENDUNG VON β-GALAKTOOLIGOSACCHRIDEN FÜR DIE HERSTELLUNG EINER KOSMETISCHEN UND/ODER PHARMAKOLOGISCH WIRKSAMEN ZUSAMMENSETZUNG |
| FR3133750B1 (fr) * | 2022-03-25 | 2025-08-29 | Helioscience | Nouvelles compositions associant des dérivés de chanvre et leur utilisation, notamment en cosmétique |
| KR102797780B1 (ko) * | 2024-11-27 | 2025-04-21 | 한국콜마주식회사 | 천연 원료 조성물 및 이를 포함하는 자외선 차단용 화장료 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3082058B2 (ja) * | 1992-05-22 | 2000-08-28 | 株式会社ホーネンコーポレーション | ６−Ｏ−α−Ｄ−ガラクトピラノシル−Ｌ−アスコルビン酸またはその塩およびその製造法並びにその用途 |
| FR2709061B1 (fr) * | 1993-08-17 | 1996-07-19 | Ladislas Robert | Utilisation d'oligosaccharides dans la prévention et le traitement du vieillissement des tissus. |
| FR2751876B1 (fr) * | 1996-07-31 | 1998-12-31 | Roc Sa | Utilisation d'un oligosaccharide comme immunomodulateur, composition dermato-cosmetique et methode de traitement cosmetique |
| FR2760365B1 (fr) * | 1997-03-07 | 2000-12-22 | Roc Sa | Composition pharmaceutique ou cosmetologique contenant au moins un retinoide, et methode de traitement cosmetique des modifications liees au vieillissement de la peau et/ou des phaneres |
| FR2762783B1 (fr) | 1997-05-02 | 2002-09-13 | Roc Sa | Utilisation d'oligosaccharides pour le traitement du tissu conjonctif et methode de traitement cosmetique mettant en oeuvre ces oligosaccharides |
| JP3665852B2 (ja) * | 1998-03-10 | 2005-06-29 | 日本甜菜製糖株式会社 | 抗アトピー性皮膚炎組成物 |
| EP1032364B1 (en) * | 1998-07-27 | 2004-03-03 | E-L Management Corp. | Topical compositions containing sialyl sugars and their derivatives |
| JP2000128770A (ja) * | 1998-08-20 | 2000-05-09 | Kanebo Ltd | 浴用組成物 |
| EP1174118A1 (de) * | 2000-06-28 | 2002-01-23 | Cognis France S.A. | Verwendung von Inulinen und Inulinderivaten |
| JP2002326924A (ja) * | 2001-05-07 | 2002-11-15 | Hayashibara Biochem Lab Inc | 洗顔料 |
| JP4410971B2 (ja) * | 2002-02-08 | 2010-02-10 | 小川香料株式会社 | ナフトール配糖体およびそれを含有する美白外用剤組成物 |
| US6890566B2 (en) * | 2002-12-11 | 2005-05-10 | Desert Whale Jojoba Company | Composition and method to whiten and exfoliate skin |
| JP2004224761A (ja) * | 2003-01-27 | 2004-08-12 | Ogawa & Co Ltd | ナフトール配糖体およびそれを含有する美白外用剤組成物 |
| JP2004224762A (ja) * | 2003-01-27 | 2004-08-12 | Ogawa & Co Ltd | ナフトール配糖体およびそれを含有する美白外用剤組成物 |
| US20050186168A1 (en) * | 2004-02-24 | 2005-08-25 | Albin Eric L. | Skin remodeling and regenerative compositions containing elastin peptide ligands having the amino acid sequence (XGXXPG)n |
| JP2009007261A (ja) * | 2007-06-26 | 2009-01-15 | Dainichiseika Color & Chem Mfg Co Ltd | 美白剤および化粧料組成物 |
| CN101909592B (zh) * | 2007-12-25 | 2013-01-30 | 花王株式会社 | 皮肤外用剂 |
| CN101999463B (zh) * | 2010-10-12 | 2012-07-04 | 李国勇 | 一种用于女性皮肤抗皱与保湿的奶粉 |
| KR101916489B1 (ko) * | 2011-01-07 | 2018-11-07 | 알러간, 인코포레이티드 | 멜라닌 변형 조성물들 및 이의 사용 방법들 |
| JP5570442B2 (ja) * | 2011-01-24 | 2014-08-13 | 株式会社シャネル化粧品技術開発研究所 | 水中油型乳化組成物及びその製造方法 |
-
2012
- 2012-03-23 GB GB1205177.7A patent/GB2500585A/en not_active Withdrawn
-
2013
- 2013-03-19 US US14/386,687 patent/US10159635B2/en active Active
- 2013-03-19 KR KR1020147029528A patent/KR102112728B1/ko active Active
- 2013-03-19 ES ES13721005T patent/ES2797535T3/es active Active
- 2013-03-19 JP JP2015500983A patent/JP6385334B2/ja active Active
- 2013-03-19 WO PCT/GB2013/050705 patent/WO2013140153A2/en not_active Ceased
- 2013-03-19 EP EP13721005.0A patent/EP2836190B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2797535T3 (es) | 2020-12-02 |
| US20150050224A1 (en) | 2015-02-19 |
| GB201205177D0 (en) | 2012-05-09 |
| US10159635B2 (en) | 2018-12-25 |
| WO2013140153A3 (en) | 2015-01-08 |
| WO2013140153A2 (en) | 2013-09-26 |
| KR20150031224A (ko) | 2015-03-23 |
| EP2836190B1 (en) | 2020-04-22 |
| EP2836190A2 (en) | 2015-02-18 |
| JP2015513357A (ja) | 2015-05-11 |
| KR102112728B1 (ko) | 2020-05-19 |
| GB2500585A (en) | 2013-10-02 |
| HK1203147A1 (en) | 2015-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mohiuddin | Skin aging & modern age anti-aging strategies | |
| Calleja-Agius et al. | Skin connective tissue and ageing | |
| EP2455097B1 (en) | Proteoglycan-containing material | |
| FR2770776A1 (fr) | Utilisations du d-xylose et de ses esters pour ameliorer la fonctionnalite des cellules de l'epiderme | |
| CN102209523A (zh) | 新抗妊娠纹活性剂以及包含其的组合物 | |
| JP6385334B2 (ja) | 糖類の化粧的および医薬的使用 | |
| Caggiati et al. | The nature of skin pigmentations in chronic venous insufficiency: a preliminary report | |
| CN119700630A (zh) | 一种青少年专研根源抗痘的组合物及其应用 | |
| CN115025001B (zh) | 一种具有多重美白祛斑功效的胜肽组合物及其应用 | |
| CN102292096A (zh) | 水果和蔬菜来源的组合物 | |
| KR20190004241A (ko) | 풋귤 추출물을 이용한 피부 주름 개선 또는 피부 보습용 조성물 | |
| CN115154360B (zh) | 一种具有美白祛斑及保湿功效的组合物及其应用 | |
| CN113440446A (zh) | 祛斑组合物及其应用和祛斑护理膜片 | |
| HK1203147B (en) | Cosmetic uses of melibiose or salts thereof | |
| CN116850081A (zh) | 一种用于敏感肌的修护组合物，冻干面膜及其制备方法 | |
| CN114748399A (zh) | 一种植物抗皱美容霜及其制备方法 | |
| Yonei et al. | Verification of improvement of periorbital wrinkles by using Asakado Skin Care | |
| KR20010075842A (ko) | 기능성 식품 | |
| EP4609848A1 (en) | Method for obtaining a composition comprising crude water extract of galega officinalis l. water, hippophae rhamnoides oil and resveratrol | |
| CN106389141A (zh) | 用于改善皮肤的组合物 | |
| CN117297992B (zh) | 一种美白组合物及其制备方法与应用 | |
| CN118634168B (zh) | 一种美白抗衰组合物、美白抗衰霜及其制备方法 | |
| Cao | GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions | |
| Roldán | Synergistic antiaging and Dermal Restorative Effects of an Oral Bioactive Procollagen and Astaxanthin Supplement with A Topical Retinyl Palmitate, Vitamin C, Hyaluronic Acid and Alpha Hidroxy Acid Based Regimen | |
| Kumar et al. | Role of different topical modalities in improvement of facial hyperpigmentation and skin rejuvenation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160308 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170512 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170831 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171102 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180427 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180709 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180807 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6385334 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |